Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials

Physician decision making in selection of second-line treatments in immune thrombocytopenia in children

(2018) Rachael F. Grace et al.   AMERICAN JOURNAL OF HEMATOLOGY

Splenectomy for immune thrombocytopenia: down but not out

(2018) Shruti Chaturvedi et al.   BLOOD

Fostamatinib for persistent/chronic adult immune thrombocytopenia

(2018) Adrian Newland et al.   Immunotherapy

Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)

(2017) Anne Zufferey et al.   Journal of Clinical Medicine

Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials

(2016) Sumit Kunwar et al.   RHEUMATOLOGY INTERNATIONAL

OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy

(2014) Peter C Taylor et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia

(2014) J. B. Bussel et al.   BLOOD

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor-  Antagonist

(2014) M. C. Genovese et al.   JOURNAL OF RHEUMATOLOGY

Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study

(2014) Michael E. Weinblatt et al.   Arthritis & Rheumatology

The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation

(2013) M Skinner et al.   BRITISH JOURNAL OF PHARMACOLOGY

Immune Thrombocytopenia

(2013) Gaurav Kistangari et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Syk-dependent signaling pathways in neutrophils and macrophages are indispensable in the pathogenesis of anti-collagen antibody-induced arthritis

(2012) N. Ozaki et al.   INTERNATIONAL IMMUNOLOGY

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia

(2011) C. Neunert et al.   BLOOD

Comprehensive analysis of kinase inhibitor selectivity

(2011) Mindy I Davis et al.   NATURE BIOTECHNOLOGY

Advances in ITP – Therapy and Quality of Life – A Patient Survey

(2011) Axel C. Matzdorff et al.   PLoS One

An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis

(2010) Michael E. Weinblatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome

(2009) B. Will et al.   BLOOD

International consensus report on the investigation and management of primary immune thrombocytopenia

(2009) D. Provan et al.   BLOOD

Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives

(2009) Jacqueline A. Guidry et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial

(2009) James B Bussel et al.   LANCET

Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial

(2008) Michael E. Weinblatt et al.   ARTHRITIS AND RHEUMATISM

Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk

(2008) A. Podolanczuk et al.   BLOOD

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

(2008) F. Rodeghiero et al.   BLOOD

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

(2008) David J Kuter et al.   LANCET

Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura

(2007) Robert McMillan et al.   AMERICAN JOURNAL OF HEMATOLOGY